Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall zyprexaZyprexa was introduced on the US market by Eli Lilly in 1996 in order to treat schizophrenia and bi polar disorder. Accounting for forty percent of Eli Lilly''s total earnings, Zyprexa is the third most prescribed drug with over 14 million users worldwide. This second generation antipsychotic and its cohorts were developed in order to reduce the instance of serious side effects associated with the first round of these medications. Ironically, since Zyprexa was introduced on the market, several Zyprexa warning statements have been issued detailing the significant adverse side effects caused by Zyprexa use.
In September of 2003, the FDA took action to mandate a Zyprexa warning label change to include information about the serious side effects of taking Zyprexa. This Zyprexa warning in America follows British and Japanese concern about the serious side effects caused by Zyprexa. These two governments issued a Zyprexa warning in 2002, cautioning Zyprexa users to be aware of their increased risk for diabetes and other glucose abnormalities.
Two recent studies caused the US federal government to mandate a Zyprexa warning. A study published in the August 2002 British Medical Journal examined almost 20,000 people who had been diagnosed with schizophrenia and found that these patients have a substantial risk of developing diabetes if treated with Zyprexa. A study conducted by Duke University in July 2002 also found that Zyprexa causes the development or worsening of diabetes. The onset of diabetes symptoms can occur rapidly, irrespective of dosage or length of Zyprexa treatment.
The Zyprexa warning that Eli Lily was required to add to their labeling was also a compulsory addition to the labeling of all second generation antipsychotics (Seroquel, Geodon, and Risperdal). This Zyprexa warning provides information about the increased risk of hyperglycemia and diabetes associated with taking this medication. Hyperglycemia, associated with ketoacidosis, coma and death, has been reported with increased frequency in Zyprexa patients.
The Zyprexa warning states that Zyprexa patients who have diabetes mellitus should be regularly monitored for changes in glucose control. Patients with risk factors for the development of Diabetes Mellitus should undergo fasting glucose testing prior to taking Zyprexa. The Zyprexa warning label states patients should be closely monitored for any signs of serious health problems, including an increase in hunger, thirst, urination, and fatigue.
The Zyprexa warning is intended to inform the public about the dangers associated with taking this medication. Unfortunately, a Zyprexa warning alone does nothing to protect Zyprexa users from these harmful and potentially deadly side effects. If you have suffered serious health problems as a result of taking Zyprexa, you may wish to contact a lawyer who can advise you of your legal rights and options in a case to recover the damages you have suffered.
On March 6, 2008, the State of Alaska provided its opening arguments in a lawsuit against the maker of the schizophrenia drug Zyprexa.
The lawsuit contends that the pharmaceutical giant Eli Lilly played down the diabetes and weight gain The maker of the popular antipsychotic drug Zyprexa is in talks to settle state and federal claims over the company’s marketing practices for more than $1 billion, potentially the... Strong new warnings were added to the label of the top-selling antipsychotic Zyprexa last week, alerting patients and physicians to the increased risk of high blood sugar and » Read More "Makers of Zyprexa may Settle Suit"
"High Blood Sugar and Weight Gain Risks"